| Index | S&P 500 | P/E | 62.65 | EPS (ttm) | 1.16 | Insider Own | 1.62% | Shs Outstand | 156.82M | Perf Week | -0.03% |
| Market Cap | 11.40B | Forward P/E | 30.82 | EPS next Y | 2.36 | Insider Trans | -0.26% | Shs Float | 156.15M | Perf Month | 0.37% |
| Enterprise Value | 11.40B | PEG | — | EPS next Q | 0.44 | Short Float | 4.84% | Perf Quarter | 0.80% | ||
| Income | 182.00M | P/S | 9.38 | EPS this Y | 6.60% | Short Ratio | 2.49 | Perf Half Y | 32.75% | ||
| Sales | 1.22B | P/B | 5.41 | EPS next Y | 15.00% | ROA | 7.03% | Short Interest | 7.55M | Perf YTD | 23.57% |
| Book/sh | 13.44 | P/C | 43.00 | EPS next 5Y | — | ROE | 8.90% | 52W High | 72.75 -0.10% | Perf Year | 19.21% |
| Cash/sh | 1.69 | P/FCF | 43.33 | EPS past 3/5Y | -12.97% 5.92% | ROIC | 7.81% | 52W Low | 43.20 68.23% | Perf 3Y | 18.14% |
| Dividend Est. | 0.32 (0.44%) | EV/EBITDA | 33.15 | Sales past 3/5Y | 2.24% 5.47% | Gross Margin | 65.77% | Volatility | 0.13% 0.17% | Perf 5Y | -43.10% |
| Dividend TTM | 0.32 (0.44%) | EV/Sales | 9.39 | EPS Y/Y TTM | 152.17% | Oper. Margin | 20.73% | ATR (14) | 0.13 | Perf 10Y | 176.94% |
| Dividend Ex-Date | Aug 24, 2026 | Quick Ratio | 3.35 | Sales Y/Y TTM | -0.33% | Profit Margin | 14.97% | RSI (14) | 57.63 | Recom | 2.54 |
| Dividend Gr. 3/5Y | 0.00% 0.00% | Current Ratio | 4.55 | EPS Q/Q | -1.89% | SMA20 | 0.14% | Beta | 1.26 | Target Price | 65.78 |
| Payout | 27.45% | Debt/Eq | 0.13 | Sales Q/Q | 1.26% | SMA50 | 0.29% | Rel Volume | 0.72 | Prev Close | 72.67 |
| Employees | 3,000 | LT Debt/Eq | 0.13 | Earnings | Nov 04 | SMA200 | 15.04% | Avg Volume | 2.80M | Price | 72.67 |
| IPO Date | Feb 09, 1989 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 0.12% 2.09% | Net Debt/EBITDA | 0.03 | Volume | 2,016,334 | Change | 0.01% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-13-26 | Downgrade | Wells Fargo | Overweight → Equal Weight | $73 |
| Jul-09-26 | Downgrade | RBC Capital | Outperform → Sector Perform | |
| Jun-30-26 | Downgrade | Benchmark | Buy → Hold | |
| Jun-30-26 | Downgrade | TD Cowen | Buy → Hold | |
| Jun-29-26 | Downgrade | Citigroup | Buy → Neutral | |
| Jun-26-26 | Reiterated | Robert W. Baird | $49 → $73 | |
| Jun-26-26 | Reiterated | Deutsche Bank | Buy | $72 → $73 |
| Jun-26-26 | Downgrade | William Blair | Outperform → Market Perform | |
| Jun-26-26 | Downgrade | Stephens & Co. | Overweight → Equal Weight | $105 → $73 |
| Jun-25-26 | Reiterated | Leerink Partners | $73 |
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2026 6/30/2026 | FY 2025 6/30/2025 | FY 2024 6/30/2024 | FY 2023 6/30/2023 | FY 2022 6/30/2022 | FY 2021 6/30/2021 | FY 2020 6/30/2020 | FY 2019 6/30/2019 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1,215 | 1,215 | 1,220 | 1,159 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 416 | 416 | 429 | 389 | — | — | — | — | — | |
| Gross Profit | 798 | 799 | 790 | 770 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 452 | 452 | 415 | 393 | — | — | — | — | — | |
| Research and Development | 94 | 95 | 99 | 97 | — | — | — | — | — | |
| Other Operating Expense | 1 | 0 | 174 | 73 | — | — | — | — | — | |
| Operating Income | 251 | 252 | 102 | 207 | — | — | — | — | — | |
| Interest Expense | 5 | 5 | 9 | 16 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -7 | -6 | 5 | -5 | — | — | — | — | — | |
| Net Income Before Taxes | 241 | 241 | 98 | 186 | — | — | — | — | — | |
| Income Taxes | 59 | 59 | 25 | 18 | — | — | — | — | — | |
| Consolidated Net Income | 182 | 182 | 73 | 168 | — | — | — | — | — | |
| Net Income From Continuing Operations | 182 | 182 | 73 | 168 | — | — | — | — | — | |
| Net Income | 182 | 182 | 73 | 168 | — | — | — | — | — | |
| EPS (Recurring) | 1.17 | 1.17 | 0.47 | 1.07 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 1.17 | 1.17 | 0.47 | 1.07 | — | — | — | — | — | |
| EPS (Diluted) | 1.16 | 1.16 | 0.46 | 1.05 | — | — | — | — | — | |
| EBITDA | 344 | 343 | 217 | 313 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 62.65 | 60.91 | 111.85 | 68.24 | — | — | — | — | — | |
| Price To Sales Ratio | 9.33 | 9.07 | 6.66 | 9.77 | — | — | — | — | — | |
| Gross Margin | 65.68 | 65.76 | 64.75 | 66.44 | — | — | — | — | — | |
| Operating Margin | 20.66 | 20.74 | 8.36 | 17.86 | — | — | — | — | — | |
| Net Margin | 14.98 | 14.98 | 5.98 | 14.50 | — | — | — | — | — | |
| Shares Outstanding | 156 | 156 | 158 | 158 | — | — | — | — | — | |
| Market Capitalization | 11,337 | 11,021 | 8,129 | 11,321 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Geist William | PRESIDENT, PROTEIN SCIENCES | Aug 15 '26 | Option Exercise | 0.00 | 33,604 | 0 | 27,050 | Nov 02 |
| Kelderman Kim | Chief Executive Officer | Aug 15 '26 | Option Exercise | 0.00 | 86,412 | 0 | 93,849 | Nov 02 |
| Bohnen Shane | SVP - General Counsel | Aug 15 '26 | Option Exercise | 0.00 | 17,540 | 0 | 11,773 | Nov 02 |
| Hippel James | CFO | Aug 15 '26 | Option Exercise | 0.00 | 39,518 | 0 | 174,694 | Nov 02 |
| HIGGINS JOHN L | Director | Sep 28 '26 | Option Exercise | 0.00 | 15,940 | 0 | 82,816 | Sep 30 |
| BAUMGARTNER ROBERT V | Director | Sep 22 '26 | Option Exercise | 0.00 | 15,940 | 0 | 62,443 | Sep 24 |
| Crouse Steven C. | President - Diag & Spatial Bi | Aug 15 '26 | Option Exercise | 0.00 | 10,846 | 0 | 12,184 | Aug 18 |
| Herr Amy E. | Director | Aug 15 '26 | Option Exercise | 0.00 | 1,178 | 0 | 789 | Aug 18 |
| Hippel James | CFO | Jul 29 '26 | Option Exercise | 47.60 | 62,068 | 2,954,437 | 215,738 | Jul 31 |
| Kelderman Kim | Chief Executive Officer | Jul 28 '26 | Option Exercise | 47.60 | 35,000 | 1,666,000 | 100,799 | Jul 30 |
| Bohnen Shane | SVP - General Counsel | Jul 23 '26 | Option Exercise | 47.60 | 448 | 21,325 | 7,697 | Jul 27 |
| Crouse Steven C. | President - Diag & Spatial Bi | Jun 02 '26 | Option Exercise | 0.00 | 600 | 0 | 6,977 | Jun 04 |
| Herr Amy E. | Director | May 08 '26 | Option Exercise | 47.60 | 6,636 | 315,874 | 6,836 | May 12 |
| Herr Amy E. | Director | May 08 '26 | Sale | 48.28 | 6,636 | 320,386 | 200 | May 12 |
| Hippel James | CFO | May 05 '26 | Option Exercise | 47.60 | 62,000 | 2,951,200 | 210,625 | May 07 |